A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom

Author:

Assaf Chalid12ORCID,Illidge Timothy M.3ORCID,Waser Nathalie4,He Mary4,Li Tina4,Zomas Athanasios5,Bent-Ennakhil Nawal5,Little Meredith6,Ortiz-Romero Pablo L.7,Pimpinelli Nicola8,Dalal Mehul6,Bagot Martine9

Affiliation:

1. Department of Dermatology, Helios Klinikum Krefeld, Lutherplatz 40, 47805 Krefeld, Germany

2. Institute of Molecular Medicine, Medical School Hamburg, 20457 Hamburg, Germany

3. Manchester NIHR BRC Centre, Christie Hospital, University of Manchester, Manchester M20 4BX, UK

4. ICON Plc, 3455 North Service Road, Unit 400, Burlington, ON L7N 3G2, Canada

5. Takeda Pharmaceuticals International AG, Thurgauerstrasse 130, CH-8152 Zurich, Switzerland

6. Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02421, USA

7. Department of Dermatology, Hospital 12 de Octubre, Institute I+12, CIBERONC, Medical School, Universidad Complutense, 28041 Madrid, Spain

8. Department of Health Sciences, Section Dermatology, Hospital P. Palagi, University of Florence Medical School, Viale Michelangiolo 41, 50125 Florence, Italy

9. Saint-Louis Hospital, Université Paris Cité, 1 Avenue Claude Vellefaux, 75010 Paris, France

Abstract

(1) Background: Most patients with mycosis fungoides (MF), a form of cutaneous T-cell lymphoma (CTCL), develop relapsed/refractory (R/R) disease following front-line systemic therapy. This report describes treatment patterns and outcomes from the subpopulation with R/R MF. (2) Methods: This observational, retrospective, cohort study analyzed patient records (1984–2016) from 27 clinical sites in Europe. Outcomes included treatments received, response to first-, second- and third-line treatment, overall survival (OS) and progression-free survival (PFS). (3) Results: Of 104 patients with MF, 100 received second-line and 61 received third-line therapy. The median (range) times from the start of first-line therapy to the first R/R MF and from the first to the second R/R MF were 11.2 (0.3–166.5) and 13.5 (0.0–174.6) months, respectively. Second-and third-line treatment options varied and comprised systemic therapies (85% and 79% of patients, respectively), radiotherapy (32% and 34%, respectively) and topical therapies (48% and 36%, respectively). The median (95% confidence interval [CI]) OS from the diagnosis of the first R/R MF was 11.5 (6.5–not reached [NR]) years and was higher with non-chemotherapy (NR) versus chemotherapy (6.5 years); the estimated median PFS (95% CI) from the time of the first R/R MF was 1.3 (1.0–2.1) years. (4) Conclusions: High rates of R/R disease were observed after second- and third-line treatments in this real-world cohort, with longer median OS in patients receiving non-chemotherapy treatment versus chemotherapy. Following the standard management of MF and using recently approved targeted therapies can help improve patient outcomes in advanced-stage MF.

Funder

Takeda Development Center Americas, Inc.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3